IL-4 drives exhaustion of CD8
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
14
07
2023
accepted:
22
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. Here, we investigate the regulation of CART cell exhaustion with three independent approaches including: a genome-wide CRISPR knockout screen using an in vitro model for exhaustion, RNA and ATAC sequencing on baseline and exhausted CART cells, and RNA and ATAC sequencing on pre-infusion CART cell products from responders and non-responders in the ZUMA-1 clinical trial. Each of these approaches identify interleukin (IL)-4 as a regulator of CART cell dysfunction. Further, IL-4-treated CD8
Identifiants
pubmed: 39266501
doi: 10.1038/s41467-024-51978-3
pii: 10.1038/s41467-024-51978-3
doi:
Substances chimiques
Interleukin-4
207137-56-2
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7921Subventions
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : K12CA090628
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : R37CA266344-01
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : CA201127
Informations de copyright
© 2024. The Author(s).
Références
Sakemura, R., Cox, M. J., Hefazi, M., Siegler, E. L. & Kenderian, S. S. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leuk Lymphoma 62, 2052–2063 (2021).
pubmed: 33682608
doi: 10.1080/10428194.2021.1894648
Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307–2315 (2023).
Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019).
pubmed: 30518502
doi: 10.1016/S1470-2045(18)30864-7
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. 380, 45–56 (2018).
Wittibschlager, V. et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int. J. Mol. Sci. 24, 5688 (2023).
Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019).
pubmed: 30837712
pmcid: 8214555
Zebley, C. C. et al. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 37, 110079 (2021).
pubmed: 34852226
pmcid: 8800370
doi: 10.1016/j.celrep.2021.110079
Beider, K. et al. Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies. Cells 11, 1140 (2022).
Wherry, E. J. T cell exhaustion 12, 492–499 (2011).
Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).
pubmed: 33795428
pmcid: 8049103
doi: 10.1126/science.aba1786
Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).
pubmed: 34788079
pmcid: 8733956
doi: 10.1126/scitranslmed.abh0272
Yu, B. et al. Epigenetic landscapes reveal transcription factors that regulate CD8+ T cell differentiation. Nat. Immunol. 18, 573-582 (2017).
Li, F., Liu, H., Zhang, D., Ma, Y. & Zhu, B. Metabolic plasticity and regulation of T cell exhaustion. Immunology 167, 482–494 (2022).
pubmed: 36088582
doi: 10.1111/imm.13575
Beltra, J.-C. et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 52, 825–841 (2020).
pubmed: 32396847
pmcid: 8360766
doi: 10.1016/j.immuni.2020.04.014
Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530–534 (2019).
pubmed: 30814732
pmcid: 6546093
doi: 10.1038/s41586-019-0985-x
Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855.e845 (2019).
pubmed: 31606264
pmcid: 6943829
doi: 10.1016/j.immuni.2019.09.013
Li, P. et al. BATF–JUN is critical for IRF4-mediated transcription in T cells. Nature. 490, 543–546 (2012).
pubmed: 22992523
pmcid: 3537508
doi: 10.1038/nature11530
McLane, L. M. et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 35, 109120 (2021).
pubmed: 33979613
pmcid: 8195461
doi: 10.1016/j.celrep.2021.109120
Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA. 116, 12410–12415 (2019).
pubmed: 31152140
pmcid: 6589758
doi: 10.1073/pnas.1905675116
Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983–995 (2021).
pubmed: 34282330
pmcid: 8319109
doi: 10.1038/s41590-021-00964-8
Yigit, B. et al. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunol Res. 7, 1485–1496 (2019).
pubmed: 31315913
doi: 10.1158/2326-6066.CIR-18-0664
Li, J., He, Y., Hao, J., Ni, L. & Dong, C. High levels of eomes promote exhaustion of anti-tumor CD8(+) T cells. Front. Immunol. 9, 2981 (2018).
pubmed: 30619337
pmcid: 6305494
doi: 10.3389/fimmu.2018.02981
Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31, 309–320 (2009).
pubmed: 19664943
pmcid: 2747257
doi: 10.1016/j.immuni.2009.06.019
Jung, I. Y. et al. Type I Interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction. Cancer Discov. 13, 1636–1655 (2023).
Jung, I. Y. et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci .Transl. Med. 14, eabn7336 (2022).
pubmed: 36350986
pmcid: 10257143
doi: 10.1126/scitranslmed.abn7336
Zhang, X. et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40, 1407–1422 e1407 (2022).
pubmed: 36240777
doi: 10.1016/j.ccell.2022.09.013
Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 576, 293–300 (2019).
pubmed: 31802004
pmcid: 6944329
doi: 10.1038/s41586-019-1805-z
Mai, D. et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proc Natl Acad Sci USA 120, e2218632120 (2023).
pubmed: 36920923
pmcid: 10041166
doi: 10.1073/pnas.2218632120
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
pubmed: 25939063
pmcid: 4458184
doi: 10.1038/nm.3838
Harush, O. et al. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica, 107, 2395–2407 (2022).
Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531–550 (2021).
pubmed: 33972771
doi: 10.1038/s41573-021-00189-2
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
pubmed: 29226797
pmcid: 5882485
doi: 10.1056/NEJMoa1707447
Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768–786.e767 (2022).
pubmed: 35750052
pmcid: 9949532
doi: 10.1016/j.ccell.2022.06.001
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
pubmed: 25075903
pmcid: 4486245
doi: 10.1038/nmeth.3047
Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 281 (2015).
pubmed: 26673418
pmcid: 4699372
doi: 10.1186/s13059-015-0843-6
Cox, M. J. et al. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia 36, 1635–1645 (2022).
pubmed: 35440691
pmcid: 9234947
doi: 10.1038/s41375-022-01572-7
Sutra Del Galy, A. et al. In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4(+) T(H)1 cell response. Sci. Immunol. 6, eabe8219 (2021).
pubmed: 34860579
doi: 10.1126/sciimmunol.abe8219
Wiede, F. et al. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. EMBO J 39, e103637 (2020).
pubmed: 31803974
doi: 10.15252/embj.2019103637
LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8(+) T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335–1347 (2019).
pubmed: 31527834
pmcid: 6754306
doi: 10.1038/s41590-019-0480-4
Liu, Y. et al. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat. Immunol. 22, 358–369 (2021).
pubmed: 33432230
doi: 10.1038/s41590-020-00850-9
Parry, H. M. et al. Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in b cell chronic lymphocytic leukaemia. Front. Immunol. 10, 2832 (2019).
pubmed: 31921116
pmcid: 6921985
doi: 10.3389/fimmu.2019.02832
Zhang, Y. et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J. Transl. Med. 20, 432 (2022).
pubmed: 36167591
pmcid: 9516829
doi: 10.1186/s12967-022-03626-x
Jinquan, T., Quan, S., Feili, G., Larsen, C. G. & Thestrup-Pedersen, K. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J. Immunol. 162, 4285–4292 (1999).
pubmed: 10201960
doi: 10.4049/jimmunol.162.7.4285
Tanaka, S. et al. The enhancer HS2 critically regulates GATA-3-mediated Il4 transcription in T(H)2 cells. Nat. Immunol. 12, 77–85 (2011).
pubmed: 21131966
doi: 10.1038/ni.1966
Carty, S. A., Koretzky, G. A. & Jordan, M. S. Interleukin-4 regulates eomesodermin in CD8+ T cell development and differentiation. PLoS ONE 9, e106659 (2014).
pubmed: 25207963
pmcid: 4160212
doi: 10.1371/journal.pone.0106659
Parikh, R. H. & Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275–285 (2023).
pubmed: 36627265
doi: 10.3322/caac.21771
Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019).
pubmed: 31042825
pmcid: 8202968
doi: 10.1056/NEJMoa1817226
Sakemura, R. et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood 139, 3708–3721 (2022).
pubmed: 35090171
pmcid: 11290597
doi: 10.1182/blood.2021012811
Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697–709 (2019).
pubmed: 30463995
pmcid: 6376281
doi: 10.1182/blood-2018-10-881722
Bagnasco, D., Ferrando, M., Varricchi, G., Passalacqua, G. & Canonica, G. W. A critical evaluation of anti-il-13 and anti-il-4 strategies in severe asthma. Int. Arch. Allergy Immunol. 170, 122–131 (2016).
pubmed: 27637004
doi: 10.1159/000447692
Thibodeaux, Q. et al. A review of dupilumab in the treatment of atopic diseases. Hum. Vaccin. Immunother. 15, 2129–2139 (2019).
pubmed: 30785362
pmcid: 6773424
doi: 10.1080/21645515.2019.1582403
Slager, R. E. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J. Allergy Clin. Immunol. 130, 516–522.e514 (2012).
pubmed: 22541248
pmcid: 3992925
doi: 10.1016/j.jaci.2012.03.030
Silva-Filho, J. L., Caruso-Neves, C. & Pinheiro, A. A. S. IL-4: an important cytokine in determining the fate of T cells. Biophys. Rev. 6, 111–118 (2014).
pubmed: 28509961
pmcid: 5427811
doi: 10.1007/s12551-013-0133-z
Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).
pubmed: 35675405
pmcid: 9177075
doi: 10.1126/sciadv.abj2820
Nowicki, T. S. et al. Infusion product TNFalpha, Th2, and STAT3 activities are associated with clinical responses to transgenic T-Cell Receptor Cell therapy. Cancer Immunol. Res. 11, 1589–1597 (2023).
pubmed: 37871333
pmcid: 10702871
doi: 10.1158/2326-6066.CIR-23-0577
Sakemura, R. et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma. Blood 134, 865–865 (2019).
doi: 10.1182/blood-2019-123277
Ito, S. E., Shirota, H., Kasahara, Y., Saijo, K. & Ishioka, C. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol. Immunother. 66, 1485–1496 (2017).
pubmed: 28733709
pmcid: 11029029
doi: 10.1007/s00262-017-2043-6
Mirlekar, B. Tumor promoting roles of IL-10, TGF-beta, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 10, 20503121211069012 (2022).
pubmed: 35096390
pmcid: 8793114
doi: 10.1177/20503121211069012
Cai, W. et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat. Commun. 10, 5800 (2019).
pubmed: 31863007
pmcid: 6925188
doi: 10.1038/s41467-019-13608-1
Sturmlechner, I. et al. p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science 374, eabb3420 (2021).
pubmed: 34709885
pmcid: 8985214
doi: 10.1126/science.abb3420
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Putri, G. H., Anders, S., Pyl, P. T., Pimanda, J. E. & Zanini, F. Analysing high-throughput sequencing data in Python with HTSeq 2.0. Bioinformatics 38, 2943–2945 (2022).
pubmed: 35561197
pmcid: 9113351
doi: 10.1093/bioinformatics/btac166
Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: Publication-Ready Volcano Plots with Enhanced Colouring and Labeling https://github.com/kevinblighe/EnhancedVolcano (2021).
Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523–530 (2014).
pubmed: 24336805
doi: 10.1093/bioinformatics/btt703
Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382–2383 (2015).
pubmed: 25765347
doi: 10.1093/bioinformatics/btv145
Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 12, 828–863 (2017).
pubmed: 28333914
pmcid: 5526071
doi: 10.1038/nprot.2017.016
Li, W. et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 16, 1–13 (2015).
doi: 10.1186/s13059-015-0843-6
Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).
pubmed: 23586463
pmcid: 3637064
doi: 10.1186/1471-2105-14-128
Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr Protoc 1, e90 (2021).
pubmed: 33780170
pmcid: 8152575
doi: 10.1002/cpz1.90
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).
pubmed: 11846609
doi: 10.1006/meth.2001.1262